|
The European Commission is today (7/2/2006) holding a media briefing
to present current EU-funded research on pandemic and avian influenza.
During thematic briefings in research facilities in Belgium, leading
European scientists will demonstrate research activities in the
field of vaccines and antivirals for avian and human influenza.
European researchers will also present some influenza projects which
have already produced significant results.
 |
| photo: Istituto Zooprofilattico
Sperimentale delle Venezie |
| |
Under the 5th Framework Programme for Research (1998-2002,
FP5) €6 million were spent on avian and pandemic
influenza in 22 institutions and national reference laboratories
across 8 European countries. Moving into the 6th Framework Programme
(2002-2006, FP6), activities were extended and reinforced with a
set of new projects launched in both the animal and human health
sectors and with more than a three-fold increase in the EU contribution
(€16 million plus a share in two large Networks
of Excellence and an Integrated Project), demonstrating a strong
EU commitment to supporting this emerging research field, as well
as providing essential support to EU policies. To date, a total
of over 120 laboratories across 21 European countries have been
funded for research on influenza within the Framework Programmes.
European research on vaccine development for pandemic
influenza has been financed since 2001 by the European Union. Early
projects worked to develop an egg-free vaccine, which is faster
and safer to produce, along with innovative application techniques.
Research is now underway with the objectives of fighting the disease
at the source (infected birds) and protecting human populations
through pandemic influenza vaccines. Future EU research will improve
vaccine efficiency by adding adjuvants, substances that boost the
body’s immune response to vaccine antigen. Additionally, research
teams are currently focused on developing a universal flu vaccine
that could provide a lifetime of protection from influenza.
The European Commission has just made a further €20
million available for research into avian and pandemic
influenza. Potential projects are invited to make an application
before 22 March 2006. This call looks to fill existing gaps in research
in a relatively short time perspective to serve as a foundation
for new and longer term research investments in the years to come.
Relating to animal health, the call covers issues such as developing
vaccines for avian species, improved diagnosis and early warning
systems, the ecology and pathogenesis of avian influenza infections,
migratory birds, avian influenza virus survival, reinforcement of
Community and national reference laboratories, technology transfer
to third countries. Relating to human health, the call covers issues
such as clinical research on pandemic influenza vaccines, better
understanding of the influenza virus and strengthening support to
surveillance. This research money is being released now to address
a pressing public health need.
During the technical briefing, several EU-funded
projects including investigations of pandemic influenza
vaccines, antiviral drugs, universal vaccines and influenza in animals
are presented. Examples include:
- NOVAFLU - developing more effective strategies
for the human vaccination against epidemic and pandemic influenza.
- AVIFLU - studying the pathogenesis of avian
influenza, as well as improving diagnosis and control of avian
infections.
- FLUAID – developing diagnostic tools
and vaccines to be used in outbreak management and in the application
of control measures based on vaccinations to combat avian influenza
infection. Leading European institutes will co-operate with Asian
laboratories as part of this research project.
- UNIVERSAL VACCINE - developing a powerful,
new, safe and easily-administered nasal vaccine for humans that
provides lifelong protection against influenza. Website: www.universalvaccine.org.
- VIZIER - identifying potential new drug targets
against RNA viruses by providing a comprehensive structural characterisation
of the replicative machinery of a carefully selected and diverse
set of viruses. Website: www.vizier-europe.org.
- VIRGIL - the first European surveillance network
capable of addressing current and emerging antiviral drugs resistance
developments in the field of viral hepatitis and influenza. Website:
www.virgil-net.org.
All these of these projects have ambitious objectives
that can only be achieved through intensive collaboration between
European and/or international research teams with complementary
expertise.
Note for editors
Background information for today’s media briefing
(electronic press kit), including speeches, project fact sheets
and portraits of researchers, is available here.
Further information on the open INFLUENZA
call is available at ec.europa.eu/research/press/2006/pr1701en.cfm.
For the thematic priority on “food
quality and safety” in the Sixth Framework Programme
(FP6): www.cordis.europa.eu/food.
For the thematic priority on “life
sciences, genomics and biotechnology for health”
in the Sixth Framework Programme (FP6): www.cordis.europa.eu/lifescihealth.
| Media
contact
Michael H. Wappelhorst, Press and information officer, Research
DG
Tel.: +32.2.298 75 75, Fax: +32.2.295 82 20
E-mail: Michael.Wappelhorst@ec.europa.eu.
Spokesperson for Science and Research
Antonia Mochan, Press and Communication DG, European Commission
Tel.: +32.2.2996 9921
E-mail Antonia.Mochan@ec.europa.eu
|
“EU-Funded
Research on Pandemic and Avian Influenza”
Media briefing, Gent & Leuven (Belgium), 7 Feb 2006
PRESS KIT
[ electronic version: ec.europa.eu/research/press/2006/pr0702en.cfm
]
Content | Presentations | Personalities
| Project fact sheets | Audiovisuals
| Content
|
| Programme |
|
Press release, 07 February 2006 EU-funded
Research on Pandemic and Avian Influenza |
|
Press release, 17 January 2006 Commission
releases new funds for avian flu research
(see also ec.europa.eu/research/press/2006/pr1701en.cfm)
|
|
| Diary Note/Media Invitation |
|
| Presentations
(in programme order) |
| Octavi Quintana Trias, European
Commission |
|
| Christian Patermann, European
Commission |
|
| John S. Oxford, London (UK) |
- |
| Ilaria Capua, Legnaro (IT) |
|
| Xavier Saelens, Ghent (BE) |
|
Kristien Van Reeth, Ghent/Merelbeke (BE)
|
|
| Johan Neyts, Leuven (BE) |
|
| Personalities (* present
in media briefing) |
Profile |
| Ilaria Capua, Legnaro (IT) [profile]
* |
PDF
(102 KB) |
HTML |
| Xavier Delamballerie, Marseille
(FR) [profile] |
PDF
(92 KB) |
HTML |
| Walter Fiers and Xavier Saelens,
Ghent (BE) [profile] |
PDF
(151 KB) |
HTML/HTML |
| Véronique Jestin, National Reference
Laboratory (FR) [profile] |
PDF
(76 KB) |
HTML |
| Runo Lina, Lyon (FR) [profile] |
PDF
(89 KB) |
HTML |
| Johan Neyts, Leuven (BE) [profile]* |
PDF
(94 KB) |
HTML |
| Albert Osterhaus, Rotterdam (NL) [profile] |
PDF
(109 KB) |
HTML |
| John S. Oxford, London (UK) [profile] *
|
PDF
(95 KB) |
HTML |
| Christian Patermann, European Commission
[CV] |
PDF
(13 KB) |
|
| Octavi Quintana Trias, European Commission
[CV] |
PDF (11 KB) |
|
| Rino Rappuoli, Siena (IT) [profile] |
PDF (559 KB) |
HTML |
| Kristien Van Reeth [CV] |
PDF
(26 KB) |
|
| John Wood, NIBSC (UK) [profile] |
PDF (101 KB) |
HTML |
| Project fact sheets
(* presented in media briefing) |
Short abstract |
Full fact sheet |
| AVIFLU |
|
|
| EPIZONE |
|
|
| ESNIP |
|
|
| ESNIP2 * |
|
|
| FLUAID |
|
|
| FLUPAN |
|
|
| FLUVACC |
|
|
| HEALTHY POULTRY |
|
|
| LAB-ON-SITE |
|
|
| NOVAFLU |
|
|
| SARS/FLU VACCINE |
|
|
| UNIVERSAL VACCINE * |
|
|
| VIRGIL * |
|
|
| VIZIER * |
|
|
DG SANCO supported projects
in the area of pandemic influenza and communicable diseases |
|
|
| Audiovisuals |
Script |
| VNR 1: EU gets ready to combat a flu pandemic |
|
| VNR 1: L'europe s'apprete à combattre une pandémie
|
|
| VNR 2: Close surveillance of avian flu in Europe |
|
| VNR 2: La grippe aviaire sous haute surveillance en Europe |
|

Video News Releases on avian and human flu are available online
|